Get started
Author

K. Church

AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: end-of-Study event free survival and achievement of developmental milestones
2017 · J. Mendell, S. Al-Zaidy, et al. · Neuromuscular Disorders · 12
AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: patients treated early with the proposed therapeutic dose were able to sit unassisted at a younger age
2017 · L. Lowes, S. Al-Zaidy, et al. · Neuromuscular Disorders · 9
Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial
2019 · J.R. Mendell, R. Shell, et al. · Journal of the Neurological Sciences · 5
S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1
2021 · JR Mendell, R Shell, et al. · Thorax · 3
SMA – THERAPY
2020 · J. Mendell, R. Shell, et al. · Neuromuscular Disorders · 3
Clinical Trial Highlights
2019 · L. Rodino-Klapac, E. Pozsgai, et al. · Neuromuscular Disorders · 3
P.066 AVXS-101 gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the phase 1 clinical trial
2019 · JR Mendell, KJ Lehman, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2
PDF
SMA THERAPIES I
2018 · R. Shell, S. Al-Zaidy, et al. · Neuromuscular Disorders · 2
DMD – THERAPY
2020 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders · 1
P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial
2019 · J. Mendell, R. Shell, et al. · Neuromuscular Disorders · 1
Protection of SNpc Neurons by Water Soluble CoQ10 in a Paraquat Induced Rat Model of Parkinson's Disease: The role of Neurotrophic Factors
2010 · Katie Facecchia, M. Somayajulu-Nitu, et al. · Free Radical Biology and Medicine · 1
Safety, β-Sarcoglycan Expression, and Functional Outcomes from Systemic Gene Transfer of rAAVrh74.MHCK7.hSGCB in LGMD2E/R4
2021 · L. R. Rodino-Klapac, E. R. Pozsgai, et al. · Neuropediatrics
LGMD
2021 · L. Rodino-Klapac, E. Pozsgai, et al. · Neuromuscular Disorders
DMD - TREATMENT
2021 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders
Limb Girdle Muscular Dystrophies
2020 · L. Rodino-Klapac, E. Pozsgai, et al. · Neuromuscular Disorders
Psy16 - Health Outcome Improvements in Spinal Muscular Atrophy Type 1 Patients With Avxs-101 Gene Replacement Therapy
2018 · S. Al-Zaidy, A.S. Pickard, et al. · Value in Health
PDF
SMA THERAPIES I
2018 · J. Mendell, S. Al-Zaidy, et al. · Neuromuscular Disorders
SMA THERAPIES I
2018 · L. Alfano, L. Lowes, et al. · Neuromuscular Disorders
AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: decreased need of ventilatory and nutritional support at End-of-Study
2017 · R. Shell, S. Al-Zaidy, et al. · Neuromuscular Disorders
Protection of SNpc neurons by water soluble CoQ 10 in a paraquat induced rat model of Parkinson's disease: The role of neurotrophic factors
2010 · Katie Facecchia, J. K. Sandhu, et al. · The FASEB Journal
Works count: 20
Citation count: 42
H-index: 3
I10-index: 1
Year
Topic
Type